Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 20/20 | 0.38 |
| ▸ | CDK2 | P24941 | 20/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 19/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 18/20 | 0.38 |
| ▸ | CDK4 | P11802 | 18/20 | 0.38 |
| ▸ | CCND1 | P24385 | 18/20 | 0.38 |
| ▸ | CDK9 | P50750 | 18/20 | 0.38 |
| ▸ | CCND3 | P30281 | 17/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 17/20 | 0.38 |
| ▸ | CDK1 | P06493 | 16/20 | 0.38 |
| ▸ | CDK3 | Q00526 | 15/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 15/20 | 0.38 |
| ▸ | CDK7 | P50613 | 8/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26491498 | 0.85 | CCNA2 (0.31) | CCNE1CDK2CCNA2CCNT1CDK4 | |
| SCHEMBL26490829 | 0.82 | CDK2 (0.38) | CCNE1CDK2CCNA2CCNT1CDK4 | |
| SCHEMBL24052512 | 0.80 | CCNA2 (0.56) | CCNE1CDK2CCNA2CCNT1CDK4 | |
| SCHEMBL20959562 | 0.79 | CCNE1 (0.39) | CCNE1CDK2CCNA2CCNT1CDK4 | |
| SCHEMBL22570067 | 0.78 | CCNE1 (0.38) | CCNE1CDK2CCNA2CCNT1CDK4 | |
| SCHEMBL24051889 | 0.75 | CCNE1 (0.59) | CCNE1CDK2CCNA2CCNT1CDK4 | |
| SCHEMBL24051873 | 0.75 | CCNA2 (0.59) | CCNE1CDK2CCNA2CCNT1CDK4 | |
| SCHEMBL20926996 | 0.75 | CDK2 (0.35) | CCNE1CDK2CCNA2CCNT1CDK4 | |
| SCHEMBL24052720 | 0.74 | CCNT1 (0.74) | CCNE1CDK2CCNA2CCNT1CDK4 | |
| SCHEMBL15249224 | 0.73 | CDK2 (0.57) | CCNE1CDK2CCNA2CCNT1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2021236650-A1 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| EP-3858835-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | CCNE1 118/4885CDK2 35/4885CCNA2 49/4885 |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | CCNE1 118/4885CDK2 35/4885CCNA2 49/4885 |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | MKI67, DPYD, PCNA | CCNE1 63/4885CDK2 17/4885CCNA2 20/4885 |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | CDK2, CCNI, CCNK | CCNE1 12/4885CDK2 1/4885CCNA2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.